KRONOS BIO INC. - COM

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

01 مايو 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

18 مارس 2025 15:01:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Announces CEO Transition and Reduction in Force

27 نوفمبر 2024 06:30:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

14 نوفمبر 2024 15:02:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

13 نوفمبر 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

05 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

23 أكتوبر 2024 07:55:00 بحسب Nasdaq GlobeNewswire

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

09 أكتوبر 2024 07:55:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

07 أكتوبر 2024 07:55:00 بحسب Nasdaq GlobeNewswire

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

25 سبتمبر 2024 07:55:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

23 سبتمبر 2024 07:55:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Announces Participation in Medical and Investor Conferences in September

03 سبتمبر 2024 07:55:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update

08 أغسطس 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

23 يوليو 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 مايو 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events

22 مايو 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer 

21 مايو 2024 07:15:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Reports First-Quarter 2024 Financial Results

09 مايو 2024 15:05:00 بحسب Nasdaq GlobeNewswire

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 أبريل 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

21 مارس 2024 06:05:00 بحسب Nasdaq GlobeNewswire